Determination of glomerular filtration rate (GFR) using MR nephrography in patients with chronic kidney disease.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-000410-37-DE

Enrollment

Registered

2007-05-15

Start date

2007-09-26

Completion date

Unknown

Last updated

2022-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease MedDRA version: 9.1 Level: LLT Classification code 10064848 Term: Chronic kidney disease

Interventions

Trade Name: Gadovist(R) Pharmaceutical Form: Solution for injection INN or Proposed INN: Gadobutrol CAS Number: 138071-82-6 Concentration unit: mmol/ml millimole(s)/millilitre Concentration type: equa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Chronic kidney disease Stages 1,2 and 3 - age over 18 years - stable kidney function 2 weeks prior study Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - chronic kidney disease stages 4 and 5 - exclusion for MR: pace maker, metal implant, ICD - pregnancy - known allergy against gadovist or inulin

Design outcomes

Primary

Measure	Time frame
Main Objective: Measurement of glomerular filtration rate using magnetic resonance and comparison to the GFR measured by inulin clearance;Secondary Objective: ;Primary end point(s): Agreement between GFR measured by MR and inulin	—

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026